Fish oil supplement tested for muscle loss in liver cancer patients
NCT ID NCT07664007
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12 weeks alongside their standard chemotherapy. The study measured changes in muscle mass using CT scans and assessed nutritional status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eicosapentaenoic acid (EPA) supplement
What this could lead to
If it works, this could point toward a simple nutritional supplement to help maintain muscle mass and reduce inflammation in people with advanced liver cancer.
What could go wrong
This was a very small, early-stage trial with only 18 participants, so results may not apply widely. The supplement may not provide meaningful benefit over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínico Universitario Lozano Blesa. IIS Aragón
Zaragoza, Zaragoza, 50009, Spain